0000000000097184

AUTHOR

Battista Borghi

showing 2 related works from this author

Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II)

2010

SummaryThis trial compared the efficacy and safety of oral dabigatran, a direct thrombin inhibitor, versus subcutaneous enoxaparin for extended thromboprophylaxis in patients undergoing total hip arthroplasty. A total of 2,055 patients were randomised to 28–35 days treatment with oral dabigatran, 220 mg once-daily, starting with a half-dose 1–4 hours after surgery, or subcutaneous enoxaparin 40 mg once-daily, starting the evening before surgery. The primary efficacy outcome was a composite of total venous thromboembolism [VTE] (venographic or symptomatic) and death from all-causes. The main secondary composite outcome was major VTE (proximal deep-vein thrombosis or non-fatal pulmonary embol…

Malemedicine.medical_specialtymedicine.drug_classArthroplasty Replacement HipInjections SubcutaneousAdministration OralLow molecular weight heparinHemorrhage030226 pharmacology & pharmacyAntithrombinsDabigatranlaw.invention03 medical and health sciencesPostoperative Complicationsoral thromboprophylaxis dabigatran flebography0302 clinical medicineDouble-Blind MethodRandomized controlled triallawHumansMedicineEnoxaparinAgedVenous Thrombosisbusiness.industryAnticoagulantAnticoagulantsVenous ThromboembolismHematologyMiddle Agedmedicine.diseaseSurvival AnalysisDabigatranSurgeryPulmonary embolismVenous thrombosisDirect thrombin inhibitorAnesthesiabeta-AlanineBenzimidazolesFemalebusinessEnoxaparin sodiummedicine.drugThrombosis and Haemostasis
researchProduct

The Hip Fracture Surgery in Elderly Patients (HIPELD) study: protocol for a randomized, multicenter controlled trial evaluating the effect of xenon o…

2012

Trials 13, 180 (2012). doi:10.1186/1745-6215-13-180

Time FactorsXenonCost-Benefit AnalysisMedicine (miscellaneous)Hospital CostHip fracturelaw.inventionStudy ProtocolFracture Fixation InternalRandomized controlled triallawFracture fixationAge FactorPharmacology (medical)Prospective StudiesHospital CostsProspective cohort studylcsh:R5-920Hip fractureDrug CostIncidence (epidemiology)Age FactorsPostoperative deliriumPsychiatric Status Rating ScaleEuropeTreatment OutcomeResearch DesignAnesthesiaAnesthetics Inhalationmedicine.symptomlcsh:Medicine (General)Humanmedicine.drugMethyl Ethersmedicine.medical_specialtyTime FactorDrug CostsSevofluraneSevofluranemedicineHumansCost-Benefit AnalysiAgedPsychiatric Status Rating ScalesHip Fracturesbusiness.industryDeliriummedicine.diseaseSurgeryClinical trialProspective StudieMethyl EtherDeliriumbusinessTrials
researchProduct